Maze Therapeutics, Inc./$MAZE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Maze Therapeutics, Inc.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Ticker
$MAZE
Sector
Primary listing
Employees
125
Headquarters
Website
MAZE Metrics
BasicAdvanced
$1B
-
-$3.82
-
-
Price and volume
Market cap
$1B
52-week high
$25.50
52-week low
$6.71
Average daily volume
507K
Financial strength
Current ratio
13.626
Quick ratio
13.294
Long term debt to equity
7.738
Total debt to equity
9.537
Profitability
EBITDA (TTM)
-123.004
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-4,831.84%
Operating margin (TTM)
-5,033.20%
Effective tax rate (TTM)
0.46%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-30.29%
Return on equity (TTM)
-62.95%
Valuation
Price to revenue (TTM)
179.883
Price to book
3.89
Price to tangible book (TTM)
3.89
Price to free cash flow (TTM)
-4.218
Free cash flow yield (TTM)
-23.71%
Free cash flow per share (TTM)
-5.513
Growth
Revenue change (TTM)
-98.48%
Earnings per share change (TTM)
-78.20%
Bulls say / Bears say
Maze closed Q2 2025 with $264.5 million in cash and equivalents, which is enough to fund operations into the second half of 2027 and advance both clinical programs without immediate funding pressure.
The Phase 1 study for MZE782 in healthy volunteers is on schedule to produce proof-of-mechanism biomarker data in Q3 2025, representing a near-term catalyst that could validate the drug’s potential in CKD and PKU.
Maze’s expanded IPO in February 2025 raised $140 million in gross proceeds, reflecting strong investor confidence and securing the financial base needed to further develop its precision medicine pipeline.
Both lead programs do not yet have clinical proof-of-concept, with Phase 1 mechanistic data for MZE782 not expected until Q3 2025 and Phase 2 data for MZE829 anticipated in Q1 2026, exposing investors to high execution risk.
MZE829 is focused on APOL1-mediated kidney disease—a genetically defined segment mainly affecting those of West African descent—potentially limiting its market size and making trial enrollment challenging due to the need for genetic screening.
Maze has not generated product revenue and admits it might run out of cash sooner than expected, which could require new funding and potentially dilute existing shareholders if development timelines slip beyond the current cash runway.
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
MAZE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Maze Therapeutics, Inc. stock?
Maze Therapeutics, Inc. (MAZE) has a market cap of $1B as of September 16, 2025.
What is the P/E ratio for Maze Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Maze Therapeutics, Inc. (MAZE) stock is 0 as of September 16, 2025.
Does Maze Therapeutics, Inc. stock pay dividends?
No, Maze Therapeutics, Inc. (MAZE) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Maze Therapeutics, Inc. dividend payment date?
Maze Therapeutics, Inc. (MAZE) stock does not pay dividends to its shareholders.
What is the beta indicator for Maze Therapeutics, Inc.?
Maze Therapeutics, Inc. (MAZE) does not currently have a Beta indicator.